Loading…
Design Therapeutics, Inc. is projected to rise to $15.87 by 2027, a +30% move from its current price of $12.18. DSGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $11.80 | $12.18 | $12.58 | +0.03% |
| Aug 3 | $11.65 | $12.19 | $12.75 | +0.06% |
| Aug 4 | $11.54 | $12.19 | $12.88 | +0.09% |
| Aug 5 | $11.44 | $12.20 | $13.00 | +0.12% |
| Aug 6 | $11.36 | $12.20 | $13.10 | +0.15% |
| Aug 7 | $11.29 | $12.20 | $13.19 | +0.19% |
| Aug 8 | $11.22 | $12.21 | $13.28 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.22 | $12.21 | $13.28 | +0.22% |
| Week 2 | $10.86 | $12.23 | $13.78 | +0.43% |
| Week 3 | $10.59 | $12.26 | $14.19 | +0.65% |
| Week 4 | $10.38 | $12.29 | $14.54 | +0.87% |
| Week 5 | $10.20 | $12.31 | $14.87 | +1.09% |
| Week 6 | $10.04 | $12.34 | $15.17 | +1.31% |
| Week 7 | $9.89 | $12.37 | $15.46 | +1.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company that researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Design Therapeutics, Inc. (DSGN) operates in the Healthcare sector with a focus on genetic disease therapeutics.
The current price is $12.62 and the market cap is $788.21M, with a rank of 2538.
Forecasted price outlook shows an upward path over time, with 2026 avg $12.62, 2027 avg $16.48, 2028 avg $23.51, 2029 avg $30.87, 2030 avg $34.64, 2031 avg $43.14, 2032 avg $45.60, 2033 avg $46.84, 2034 avg $61.03, 2035 avg $75.22, 2040 avg $117.17, and 2050 avg $327.43. ROI figures rise accordingly, from 0 in 2026 to 30.6% in 2027, 86.3% in 2028, 144.6% in 2029, 174.5% in 2030, 241.8% in 2031, 261.3% in 2032, 271.1% in 2033, 383.6% in 2034, 496% in 2035, 828.4% in 2040, and 2494.5% in 2050, with bullish sentiment shaping the longer horizon.
A major floor 25.0% below — a decisive break under it would weaken the trend.
The nearest floor, 4.5% below — buyers have tended to step in here.
The nearest ceiling, 28.4% above — a clean break opens room to run.
A major ceiling 40.9% above — clearing it would confirm fresh momentum.
Key DSGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DSGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.11 | Buy | $12.18 | Buy |
| MA 10 | $11.97 | Buy | $12.28 | Sell |
| MA 20 | $13.07 | Sell | $12.60 | Sell |
| MA 50 | $12.34 | Sell | $12.63 | Sell |
| MA 100 | $12.31 | Sell | $12.08 | Buy |
| MA 200 | $10.62 | Buy | $10.70 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.63 | Neutral |
| Stoch RSI (14) | 54.40 | Neutral |
| CCI (20) | -49.56 | Neutral |
| Williams %R (14) | -73.04 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | -9.91 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 26.96 | Neutral |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -0.99 | Sell |
| Ultimate (7,14,28) | 50.16 | Neutral |
| Momentum (10) | -0.39 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 12.35 | Sell |
| ADX (14) | 19.72 | Neutral |
| ATR (14) | 0.36 | Info |
The 30-day technical picture is bullish. The sentiment is BULLISH and RSI(14) is 50.
The 50-day simple moving average is $12.31, while the 200-day simple moving average is $10.59.
Key levels show support at $11.63 and resistance at $15.64, framing a 30-day range from $10.23 to $15.58. Annualized volatility is 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.69 | $12.18 | $17.26 | 0% | Neutral | |
| $12.47 | $15.87 | $21.48 | +30% | Bullish | |
| $17.17 | $22.60 | $31.93 | +86% | Bullish | |
| $21.98 | $29.77 | $43.47 | +144% | Bullish | |
| $24.07 | $33.40 | $50.15 | +174% | Bullish | |
| $29.30 | $41.58 | $63.96 | +241% | Bullish | |
| $30.40 | $44.06 | $69.24 | +262% | Bullish | |
| $30.57 | $45.19 | $72.41 | +271% | Bullish | |
| $38.95 | $58.68 | $95.73 | +382% | Bullish | |
| $47.23 | $72.45 | $120.15 | +495% | Bullish | |
| $67.75 | $112.89 | $200.59 | +827% | Bullish | |
| $163.98 | $316.08 | $620.38 | +25.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $8.69 | $12.18 | $15.15 | +0.00% |
| September 2026 | $10.39 | $12.35 | $15.14 | +1.39% |
| October 2026 | $10.45 | $12.53 | $15.55 | +1.45% |
| November 2026 | $11.03 | $13.31 | $16.69 | +6.23% |
| December 2026 | $11.24 | $13.65 | $17.26 | +2.53% |
Click any year to see its month-by-month DSGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DSGN to range from $8.69 to $17.26 through 2026. The $12.18 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The DSGN price prediction for 2027 points to an average of $15.87 (low $12.47, high $21.48) — a potential gain of +30% on today's $12.18. Momentum favours further upside here.
In 2028, DSGN is projected to trade between $17.17 and $31.93, averaging $22.60 — a potential gain of +86% from today's $12.18. That is up +42% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Design Therapeutics, Inc.'s 2029 outlook centres on $29.77, within a $21.98 to $43.47 range. That is up +32% on the projected 2028 average. That marks a +144% change versus current levels. Momentum favours further upside here.
By 2030, DSGN could reach as high as $50.15, with a base case around $33.40 and support toward $24.07 — roughly +174% from $12.18. Buyers look set to stay in control over this stretch.
Expect DSGN to range from $29.30 to $63.96 through 2031. The $41.58 average target implies a +241% move from current prices. That is up +25% on the projected 2030 average. Momentum favours further upside here.
The DSGN price prediction for 2032 points to an average of $44.06 (low $30.40, high $69.24) — a potential gain of +262% on today's $12.18. Buyers look set to stay in control over this stretch.
In 2033, DSGN is projected to trade between $30.57 and $72.41, averaging $45.19 — a potential gain of +271% from today's $12.18. That is up +3% on the projected 2032 average. Momentum favours further upside here.
Design Therapeutics, Inc.'s 2034 outlook centres on $58.68, within a $38.95 to $95.73 range. That is up +30% on the projected 2033 average. That marks a +382% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, DSGN could reach as high as $120.15, with a base case around $72.45 and support toward $47.23 — roughly +495% from $12.18. Momentum favours further upside here.
Expect DSGN to range from $67.75 to $200.59 through 2040. The $112.89 average target implies a +827% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The DSGN price prediction for 2050 points to an average of $316.08 (low $163.98, high $620.38) — a potential gain of +25.0x on today's $12.18. Momentum favours further upside here.
Investing $1,000 in DSGN today (≈ 82.101806 DSGN) could be worth
$25,950.45
+$24,950.45 (+2495%) by 2050 · US Dollar
Based on the average projected DSGN price of $316.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DSGNwould be worth at today's price.
$1,000 invested in DSGN on Jul 31, 2025 (≈ 258.39794 DSGN) would be worth
$3,147.29
+$2,147.29 (+214.7%) today · 3.15× · US Dollar
Based on a DSGN entry price of $3.87 vs. today's $12.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.78 | $1,033.96 | +3.4% |
| 1 month ago | $14.66 | $830.83 | -16.9% |
| 3 months ago | $13.3 | $915.79 | -8.4% |
| 6 months ago | $10.41 | $1,170.03 | +17.0% |
| 1 year ago | $3.87 | $3,147.29 | +214.7% |
| All time (5.0y) ago | $15.87 | $767.49 | -23.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DSGN forecast.
Our base-case forecast reaches $24.00 around 2029.
Implied market cap at $24.00: $1.5B
The multi-year forecast points to a consistently bullish trajectory over the long horizon. The path of average prices climbs across the years, with 2026 avg $12.62 and 2050 avg $327.43 (min $169.71, max $643.03), and substantial upside reflected in the later years.
In 2030 the avg price is $34.64 with an ROI of 174.5% and bullish sentiment; the min is $24.96 and the max is $52.04.
By 2040 the avg price is $117.17 with an ROI of 828.4% and bullish sentiment, and by 2050 the avg price is $327.43 with an ROI of 2494.5% and bullish sentiment.
These forecasts sit in the context of a company focused on lead product candidates for Friedreich Ataxia, Myotonic Dystrophy Type-1, Fuchs Endothelial Corneal Dystrophy, and Huntington's Disease, but they are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $34.64; Min $24.96; Max $52.04; ROI 174.5%; sentiment bullish.
Yes. The forecast shows 2026 avg $12.62, then 2027 avg $16.48, 2028 avg $23.51, and 2029 avg $30.87, with bullish sentiment expanding in the period.
Yes. The forecast includes 2040 max $208.29 and 2050 max $643.03, so surpassing $200 is within the forecast.
Low $10.23, High $15.58.
Current price $12.62; Market cap $788.21M; Rank 2538.
Design Therapeutics, Inc. Community Discussion
0Share your Design Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.